Ipsen Moves Aggressively On U.S. Strategy, Builds Out Commercial and R&D Infrastructure
This article was originally published in The Pink Sheet Daily
Executive Summary
As part of an ongoing strategic reorganization, Ipsen announced the appointment of a nine-member U.S. leadership team to execute on the growth of its neurology and endocrinology franchises.